Jason S. Slakter, M.D. is a board certified retinal and macular disease specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner at Vitreous-Retina-Macula Consultants of New York.
Dr. Slakter is a native of Los Angeles, California. He graduated from Pomona College in 1979 and was elected to Phi Beta Kappa fraternity and received his Doctor of Medicine degree from Albert Einstein College of Medicine in 1983 and was elected to Alpha Omega Alpha fraternity. He completed residency training in ophthalmology at the Manhattan Eye, Ear & Throat Hospital in 1987 and a year of fellowship training in medical and surgical retinal diseases also at Manhattan Eye, Ear & Throat Hospital in New York.
Dr. Slakter was Assistant Clinical Professor of Ophthalmology at the College of Physicians and Surgeons, Columbia University from 1996 to 2001. He joined the Department of Ophthalmology at New York University School of Medicine in New York as a Clinical Professor of Ophthalmology in 2001. Dr. Slakter's principal clinical and research interests are in the areas of macular disease, management of exudative age-related macular degeneration, retinal vascular disease, and central serous chorioretinopathy. He created and is the director of the Digital Angiography Reading Center (DARC), which is one of the largest centers for image evaluation for clinical trials of posterior segment disease with over 900 certified clinical sites in over 44 countries worldwide, serving as a key resource for industry-sponsored studies of new treatments for retinal disorders.
Dr. Slakter is a member of numerous medical organizations including the American Ophthalmological Society, Retina Society, Macula Society, American Society of Retina Specialists, New York Ophthalmological Society and the Manhattan Ophthalmology Society. Dr. Slakter was the founding Editor-in-Chief of Retinal Physician journal. He has been the recipient of many awards including The Macula Society's Richard and Hinda Rosenthal Award for outstanding contribution to the treatment of ocular disease by an individual under the age of 45, the Helen Keller Manhattan League Award in 2003 and Senior Honor Award from the American Academy of Ophthalmology in 2004. Dr. Slakter has published more than 100 papers and book chapters.
Dr. Slakter also serves as the Chief Executive Officer and President of Ohr Pharmaceutical, Inc. a biotechnology company focused on developing new therapeutics to meet unmet needs for a variety of ocular conditions.